Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
FDA Accepts Shionogi’s Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Notice of Acquisition of TORII PHARMACEUTICAL CO., LTD. as a Wholly-Owned Subsidiary
Supplemental material for financial results for the 1st quarter of fiscal year 2025
Shionogi, Apr-Jun (1Q) Net Income Increases by 28%
Consolidated Financial Results for the First Quarter of Fiscal Year 2025 (IFRS)
1st Quarter of Fiscal 2025 Financial Results
ViiV Healthcare’s Presentation on the VOLITION Study of Long-Acting Injectable Cabenuva in HIV Treatment
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Corporate Governance Report
[Summary]Shionogi Submits sNDA for Ensitrelvir in Japan for Pediatric COVID-19 Age 6 and older
Notice of Results of Tender Offer for Shares of TORII PHARMACEUTICAL CO., LTD. (Securities Code: 4551)
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
(Amendment) Notice of Amendment to “Notice of Tender Offer for Shares of TORII” Due to Submission of Amendment to Tender Offer Statement
Acceptance of a New Drug Application for Naldemedine, a Treatment for Opioid-Induced Constipation, in China
(Amendment) Notice of Amendment to “Notice of Tender Offer for Shares of TORII” and Public Notice Following Amendment to Tender Offer Statement
Amendments to Articles of Incorporation
Financial results for the year ended March 31, 2025
Shionogi, 6% Increase in Net Income for The Current Fiscal Year, Dividend Effectively Increased
FY2024 Finacial Results
Consolidaterd Financial Resauts for Fiscal Year 2024 (IFRS)